Does COBIMETINIB Cause Malignant neoplasm progression? 35 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 35 reports of Malignant neoplasm progression have been filed in association with COBIMETINIB (Cotellic). This represents 0.9% of all adverse event reports for COBIMETINIB.
35
Reports of Malignant neoplasm progression with COBIMETINIB
0.9%
of all COBIMETINIB reports
9
Deaths
11
Hospitalizations
How Dangerous Is Malignant neoplasm progression From COBIMETINIB?
Of the 35 reports, 9 (25.7%) resulted in death, 11 (31.4%) required hospitalization, and 3 (8.6%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for COBIMETINIB. However, 35 reports have been filed with the FAERS database.
What Other Side Effects Does COBIMETINIB Cause?
Diarrhoea (412)
Off label use (411)
Rash (369)
Pyrexia (332)
Death (231)
Nausea (206)
Fatigue (198)
No adverse event (178)
Vomiting (168)
Acute kidney injury (133)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which COBIMETINIB Alternatives Have Lower Malignant neoplasm progression Risk?
COBIMETINIB vs COCAETHYLENE
COBIMETINIB vs COCAINE
COBIMETINIB vs COCOA BUTTER\PHENYLEPHRINE
COBIMETINIB vs COD LIVER OIL
COBIMETINIB vs CODEINE